BATTLE Trial: Bare Metal Stent Versus Paclitaxel Eluting Stent in the Setting of Primary Stenting of Intermediate Length Femoropopliteal Lesions
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Jun 2019
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary)
- Indications Arteriosclerosis; Peripheral artery restenosis; Peripheral vascular disorders
- Focus Therapeutic Use
- Acronyms BATTLE
- 07 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Mar 2016 Planned End Date changed from 1 Mar 2018 to 1 Sep 2018, as reported by ClinicalTrials.gov.
- 07 Mar 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2017, as reported by ClinicalTrials.gov.